Novosanis, Distribuidora GAP Signs Agreement
News Jul 26, 2016
Novosanis has announced a new distribution partnership with Distribuidora GAP short for Distribuidora Química y Hospitalaria GAP. As part of this agreement, Distribuidora GAP will sell the Novosanis’ Colli-PeeTM, a medical device suited for collection of first void urine, in Mexico. Distribuidora GAP is one of Mexico’s largest distributors dedicated to the promotion, sales and distribution of reagents, hospital materials and equipment for clinical laboratories.
“Distribuidora GAP has a strong expertise in the field of distribution of medical devices to labs and hospitals. This distribution partnership will strengthen the international position of Novosanis in Mexico.” says Vanessa Vankerckhoven, CEO Novosanis.
Jesus Ortega Martínez, CEO at Distribuidora GAP: “We’re excited to distribute Colli-PeeTM to laboratories and hospitals in Mexico. Novosanis’ device allows easier and more patient-friendly detection of the Human papillomavirus that can lead to cervical cancer. This is still an important health problem to women living in rural and suburban regions of Mexico. Thanks to Colli-PeeTM we can have new ways to reach out to these remote groups of women. We believe this partnership will help us to fight HPV and save many women from cervical cancer.”
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE